FDAsafety guidance83% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Eli Lilly.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Sleep-Wake Disorders
- Sub-indication
- General
Related signal: Lilly acquires Centessa Pharmaceuticals to enhance sleep-wake disorder treatments